Gyre Therapeutics to Acquire Cullgen in All-Stock Deal

Pulmatrix to Merge with Cullgen to Form Nasdaq-Listed Company Focused on Targeted Protein Degradation

November 13, 2024

Biotechnology

Pulmatrix announced a proposed merger with Cullgen to create a Nasdaq-listed biopharmaceutical company focused on targeted protein degradation, including three degrader programs in or about to begin Phase 1 clinical trials. The combined company is expected to operate as Cullgen Inc. headquartered in San Diego, California, with closing expected by end of March 2025 subject to approvals. As part of the merger agreement, Pulmatrix plans to divest certain assets, and Pulmatrix stockholders are expected to receive a special cash dividend contingent on net cash at closing.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Novartis to Acquire Gyroscope Therapeutics

December 22, 2021

Healthcare Services

Novartis entered into a definitive agreement to acquire all of the outstanding share capital of UK-based ocular gene therapy company Gyroscope Therapeutics. The deal includes an upfront payment of $800 million and potential additional milestone payments of up to $700 million, subject to customary regulatory approvals.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Pharmaceuticals

Gilead Sciences, Inc. agreed to acquire CymaBay Therapeutics, Inc. for an equity value of approximately $4.3 billion, or $32.50 per share in cash. The acquisition adds CymaBay’s investigational lead asset seladelpar for the treatment of primary biliary cholangitis (PBC), complementing Gilead’s existing liver portfolio.

HiberCell Acquires Genuity Science, Inc.

August 16, 2021

Biotechnology

HiberCell, a clinical-stage oncology company, acquired Genuity Science, a genomics and multi‑omic analytics company with an advanced AI/ML platform, to integrate next‑generation computational capabilities into its translational oncology efforts. The stock acquisition brings Genuity and its subsidiaries into HiberCell, provides approximately $100 million in cash and existing partnership earnouts, and is intended to accelerate HiberCell's clinical programs and expand its preclinical pipeline.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.